CriticalReversible MAO-A inhibitor (RIMA)×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Vortioxetine acts on serotonin receptors and inhibits the serotonin transporter (vortioxetine SmPC, European Medicines Agency, EMA, section 5.1). Vortioxetine can cause serotonin syndrome on its own, and the risk rises with drugs that affect serotonin metabolism, including MAO inhibitors (vortioxetine SmPC, EMA, section 4.4). The half-life of moclobemide is about 3 hours (moclobemide SmPC, AEMPS, section 5.2). Vortioxetine has a half-life of 66 hours and reaches steady state in about 2 weeks (vortioxetine SmPC, EMA, section 5.2). The documents describe no interaction through liver enzymes. CYP2D6 is the main enzyme that metabolises vortioxetine, and the moclobemide SmPC names moclobemide as an inhibitor of only one CYP enzyme, CYP2C19. A single dose of omeprazole, a CYP2C19 inhibitor, did not change vortioxetine pharmacokinetics (vortioxetine SmPC, EMA, sections 4.5 and 5.2; moclobemide SmPC, AEMPS, section 4.5).
Symptoms
Serotonin syndrome presents with changes in mental state (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, raised body temperature), neuromuscular disturbances (overactive reflexes, poor coordination) and nausea, vomiting or diarrhoea (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.4). With drugs that affect serotonin metabolism, including monoamine oxidase (MAO) inhibitors, vortioxetine also carries a higher risk of neuroleptic malignant syndrome, and both conditions can be life-threatening (vortioxetine SmPC, EMA, section 4.4). The US vortioxetine label adds delirium, dizziness, sweating, flushing, tremor, muscle rigidity, myoclonus and seizures (vortioxetine label, US Food and Drug Administration, FDA, section 5.2). The moclobemide SmPC describes isolated cases of a severe combination of high fever, confusion, overactive reflexes and myoclonus, signs of excess serotonin activity, when moclobemide was combined with other antidepressants (moclobemide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5).
Management
The combination is contraindicated: the vortioxetine summary of product characteristics (SmPC) contraindicates selective inhibitors of monoamine oxidase (MAO) type A and names moclobemide (vortioxetine SmPC, European Medicines Agency, EMA, sections 4.3 and 4.5). The US vortioxetine label contraindicates MAO inhibitors used to treat psychiatric disorders (vortioxetine label, US Food and Drug Administration, FDA, section 4), and moclobemide is an antidepressant from this group (moclobemide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). The moclobemide SmPC advises caution with other antidepressants that raise serotonin (moclobemide SmPC, AEMPS, sections 4.4 and 4.5). If the combination cannot be avoided, give the added drug at the lowest dose under close clinical monitoring for serotonin syndrome (vortioxetine SmPC, EMA, section 4.5). The documents give different switching intervals. The US label says to start vortioxetine at least 14 days after stopping an MAO inhibitor used for psychiatric disorders (FDA vortioxetine label, sections 2.4 and 4). The moclobemide SmPC, by contrast, allows another antidepressant to start the day after moclobemide is stopped (moclobemide SmPC, AEMPS, section 4.5). The US label also says to start moclobemide at least 21 days after stopping vortioxetine (FDA vortioxetine label, sections 2.4 and 4). The EU vortioxetine SmPC gives a 14-day interval only for irreversible non-selective MAO inhibitors (vortioxetine SmPC, EMA, section 4.5). If serotonin syndrome develops, stop vortioxetine at once and start symptomatic treatment (vortioxetine SmPC, EMA, section 4.4). Stop other serotonergic drugs at once as well (FDA vortioxetine label, section 5.2). Keep the patient under medical supervision, with admission to hospital if needed (moclobemide SmPC, AEMPS, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.3 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, consultado 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.5 y 5.2
- FDA: TRINTELLIX (vortioxetine) tablets prescribing information (Takeda) (2025)– FDA, DailyMed setid 1a5b68e2-14d0-419d-9ec6-1ca97145e838 (Takeda Pharmaceuticals America), revisión 02/2025 (versión 18, vigente desde 05.03.2025), secciones 2.4, 4, 5.2 y 7.1